{'fraction_non_alphanumeric': 0.015985790408525755, 'fraction_numerical': 0.0, 'mean_word_length': 6.230769230769231, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacokinetics and Pharmacodynamics of Ceftizoxime in Patients with Dosages Adjusted for Renal Function

Study Objective. Our institution developed dosing guidelines for patients with renal impairment based on pharmacokinetic data and class‐specific pharmacodynamics. Ceftizoxime was chosen as a model agent to evaluate if the modified guidelines achieved similar minimal plasma concentration (Cpmin) and time above the minimum inhibitory concentration of the infecting organism (T>MIC) in patients with renal impairment versus those with normal renal function.